Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: The San Francisco PEP study

Journal of Infectious Diseases

Volumn 183, Issue 5, 2001, Pages 707-714

  Kahn, James O ^a   Martin, Jeffrey N ^a,b,c   Roland, Michelle E ^a   Bamberger, Joshua D ^d,e   Chesney, Margaret ^b   Chambers, Margaret ^b   Franses, Karena ^a,b   Coates, Thomas J ^b   Katz, Mitchell H ^a,c,e  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b Center for AIDS Prevention Studies   (United States)

^c Department of Epidemiology and Biostatistics ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA;

ADULT; ANOREXIA; ARTICLE; DIARRHEA; DRUG EXPOSURE; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; PROPHYLAXIS; RISK MANAGEMENT; SEXUAL INTERCOURSE; SEXUAL TRANSMISSION; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CONTACT TRACING; COUNSELING; DIDANOSINE; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NELFINAVIR; PATIENT COMPLIANCE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; RISK-TAKING; SEXUALLY TRANSMITTED DISEASES, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; ZIDOVUDINE;

EID: 0035283026     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/318829     Document Type: Article

References (38)

1. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Groups Protocol 076 Study Group
2. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immuno-deficiency virus
3. Trends in perinatal transmission of HIV/AIDS in the United States
4. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomized controlled trial
5. Short-course oral zidovudine for prevention of mother-to child transmission of HIV-1 in Abidjan, Côte d'Ivoire: A randomized trial
6. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial
7. A case-control study of HIV seroconversion in health care workers after percutaneous exposure
8. Antiretroviral therapy for HIV infection 1998
9. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
10. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
11. Management of possible sexual, injecting-drug use or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy
12. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use
13. Sexual transmission of HIV
14. Gerberding. The care of persons with recent sexual exposure to HIV
15. Social cognitive theory and exercise of control over HIV infection
16. Coping effectiveness training for men living with HIV: Preliminary findings
17. Post-exposure prophylaxis for HIV infection in gay and bisexual men: Implications for the future of HIV prevention
18. Experience of healthcare workers (HCWs) taking postexposure prophylaxis (PEP) after occupational human immunodeficiency virus (HIV) exposures: Findings of the HIV PEP registry
19. Surveillance of HIV Infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood
20. Zidovudine toxicity in uninfected healthcare workers. Italian Registry of Antiretroviral Prophylaxis
21. Sexual transmission of HIV: Infectiousness and prevention
22. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus
23. Animal studies of prophylaxis
24. HIV infection in homosexual and bisexual men 18 to 29 years of age: The San Francisco Young Men's Health Study
25. Feasibility of human immunodeficiency virus vaccine trials in homosexual and bisexual men in the United States: Risk behavior, seroincidence, and willingness to participate
26. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas
27. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV
28. Is post-exposure prophylaxis affordable?
29. A reality check: The cost of making post-exposure prophylaxis available to gay and bisexual men at high sexual risk
30. A tale of two futures: HIV and antiretroviral therapy in San Francisco
31. Is offering post-exposure prevention for sexual exposures to HIV related to sexual risk behavior in gay men?
32. Sexual risk behaviors among heterosexual HIV serodiscordant couples in the era of post-exposure prevention and viral suppressive therapy
33. Post-exposure prophylaxis for HIV infection in gay and bisexual men: Implications for the future of HIV prevention
34. Effects of HIV counseling and testing on sexual risk behavior: A meta-analytic review of published research, 1985-1997
35. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: A randomized controlled trial
36. From epidemiological synergy to public health policy and practice: The contribution of other sexually transmitted diseases to sexual transmission of HIV infection